Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2026; 18(11): 124800
Published online Nov 27, 2026. doi: 10.4254/wjh.124800
Published online Nov 27, 2026. doi: 10.4254/wjh.124800
Molecular pathophysiology of hepatocellular carcinoma: Role of tumor microenvironment and vascular signaling
Deepti Sharma, Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi 110070, India
Babu Lal Meena, Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Vanya Garg, Department of Molecular and Cellular Medicines, Institute of Liver and Biliary Sciences, New Delhi 110070, India
Author contributions: Sharma D, Meena BL contributed to concept, design and writing of article; Garg V contributed to concept, design and writing of article; all authors approved the manuscript and its submission to the journal.
AI contribution statement: The authors declare that no AI tools were used in the development or writing of this manuscript and take full responsibility for its integrity, accuracy, and originality.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Deepti Sharma, MD, Additional Professor, Department of Radiation Oncology, Institute of Liver and Biliary Sciences, Vasant Kunj, New Delhi 110070, India. drdeeptisharma16@gmail.com
Received: June 24, 2026
Revised: August 1, 2026
Accepted: October 10, 2026
Published online: November 27, 2026
Processing time: 148 Days and 21.7 Hours
Revised: August 1, 2026
Accepted: October 10, 2026
Published online: November 27, 2026
Processing time: 148 Days and 21.7 Hours
Core Tip
Core Tip: Hepatocellular carcinoma (HCC) progression is governed by dynamic interactions between tumor genomics, stromal elements, hypoxia, and aberrant vascular signaling. The success of immune-antiangiogenic combinations validates the concept that vascular normalization and immune reprogramming are biologically interconnected processes. This review integrates molecular, tumor microenvironment-level, and clinical trial data to define biomarker-aligned, mechanism-based vascular and immune targeting strategies aimed at achieving more durable disease control in advanced HCC.